Women's Health:
Updates in Breast Cancer Management

November 17, 2026

SALT.
6820 Spring Creek Rd, Rockford, IL

UI Health | UIC
UNIVERSITY OF ILLINOIS CANCER CENTER

This activity is jointly provided by Global Education Group (Global) and Shafer Health Strategies.

global EDUCATION GROUP
A member of the Vocate system.

SHS
SHAFER HEALTH STRATEGIES

Target Audience

The educational design of this activity addresses the needs of oncologists, nurse practitioners, and physician assistants involved in the treatment of patients with breast cancer.

Statement of Need/Program Overview

Advances in targeted therapies, immunotherapies, and biomarker-driven care have transformed oncology, yet adoption of precision medicine remains inconsistent—particularly in community settings and among underserved populations facing barriers to screening, diagnosis, and access to novel treatments. Ongoing gaps in biomarker testing, treatment sequencing, and multidisciplinary coordination highlight the need for evidence-based CME.

The University of Illinois Cancer Center serves a diverse, medically underserved population with persistent cancer disparities. This activity aims to equip clinicians with practical, evidence-based strategies in precision diagnostics, treatment selection, toxicity management, and equitable cancer care to improve patient outcomes.

Educational Objectives

After completing this activity, the participant should be better able to:

- Review updated clinical evidence and guideline recommendations to treatment sequencing and planning
- Identify biomarker-driven decision-making into patient management.
- Identify treatment-related toxicities using current best practices.
- Explain how to improve multidisciplinary coordination across oncology specialties.
- Discuss how to address disparities in cancer care affecting hard-to-reach populations.

Faculty

VK Gadi, MD, PhD
Cancer Center Deputy Director
Assistant Professor of Clinical Medicine
Division of Hematology and Oncology
College of Medicine, University of Illinois

Joint Accreditation Statement

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Shafer Health Strategies. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point and medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Global Contact Information

For information about the Joint Accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the activity, application for credit and evaluation form. Participants must also score at least 70% on the post-test. The evaluation and post-test will be emailed to you after the end of the activity. Please check your spam folder.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the *Standards for Integrity and Independence in Accredited CE*, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

The ***faculty*** have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	***Reported Financial Relationship***
VK Gadi, MD, PhD	**Consulting Fee (e.g., Advisory Board)** Puma Biotechnology, Daiichi Sankyo, Novartis, AstraZeneca, Genentech, Bayer, Gilead, Hologic, Lilly, Pfizer **Contracted Research (Principal Investigators must provide information, even if received by the institution)** Illumina, Novartis, Lilly, Gilead, Agendia, Genentech, Phrontline **Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed)** Tempus

The following ***planners and managers*** at Global and Shafer Health Strategies have no relevant financial relationships with ineligible companies to disclose.

The ***planners and managers*** have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	*Reported Financial Relationship*
VK Gadi, MD, PhD	**Consulting Fee (e.g., Advisory Board)** Puma Biotechnology, Daiichi Sankyo, Novartis, AstraZeneca, Genentech, Bayer, Gilead, Hologic, Lilly, Pfizer **Contracted Research (Principal Investigators must provide information, even if received by the institution)** Illumina, Novartis, Lilly, Gilead, Agendia, Genentech, Phrontline **Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed)** Tempus

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Shafer Health Strategies do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.